NIHR BioResource 2022 Renewal
Research type
Research Tissue Bank
IRAS ID
313104
Contact name
Rose Eichenberger
Contact email
Research summary
NIHR BioResource for Translational Research
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
22/EE/0230
Date of REC Opinion
14 Oct 2022
REC opinion
Further Information Favourable Opinion
Data collection arrangements
Recruitment takes place in a variety of settings and participants are asked for consent for the provision of a blood or saliva sample for DNA sequencing and analysis, access to medical/health records, social and educational records and permission to be contacted for future studies. Questionnaires are used to gain health and lifestyle information on the participant. In certain cohorts cohort, imaging and results from neurological testing (e.g. COVID-CNS), or biopsy samples (IBD) are also stored.
A web-based contact management system hosted on secure servers in the data centre holds participant consent and contact details. Separate databases hold extensive genetic, lifestyle and environmental data about the participants.Samples are stored in national repositories approved by the NIHR Bioresource.
Access to samples and/or data is managed through applications from researchers. The Scientific Advisory Board / National Participant Advisory Group review applications based on their scientific justification, genotypic, phenotypic and clinical requirements and benefit to patients. Stage 2 recall study applications are also assessed in regard to burden to volunteers, and feasibility.
Research programme
The NIHR BioResource is a prospective collection of samples and associated data on ~230,000 individuals. The BioResource also holds the Genotypic and Phenotypic data associated with each participant. The NIHR BioResource covers the general population, the Young People’s BioResource and the COVID-19 cohort. In addition it cover national programmes and common diseases cohorts, including Inflammatory Bowel Disease (IBD BioResource), Immune-Mediated Inflammatory Diseases (IMID), Non-Alcoholic Fatty Liver Disease (NAFLD) and the Mental Health cohorts GLAD and EDGI. The NIHR BioResource is funded by the National Institute for Health and Care Research. The BioResource is managed by a Steering Committee and an Oversight Board, which has members from other BioResource centres, key stakeholders (e.g. NHSBT), and patient and public representatives. The NIHR BioResource has received a favourable opinion from East of England Research Ethics Committee – Cambridge Central. Standard Operating Procedures are in place to facilitate the smooth operation of the BioResource. Study documentation has been reviewed by Patient and Public advisory groups. The NIHR BioResource has provided a panel of samples and data which has resulted in more than 250 scientific publications to date.
Storage license
12315
RTBTitle
NIHR BioResource for Translational Research